Market capitalization | $427.31m |
Enterprise Value | $306.02m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 518.68 |
P/S ratio (TTM) P/S ratio | 724.25 |
P/B ratio (TTM) P/B ratio | 2.17 |
Revenue (TTM) Revenue | $590.00k |
EBIT (operating result TTM) EBIT | $-210.02m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
12 Analysts have issued a Prime Medicine forecast:
12 Analysts have issued a Prime Medicine forecast:
Jun '24 |
+/-
%
|
||
Revenue | 0.59 0.59 |
-
|
|
Gross Profit | -7.88 -7.88 |
49%
49%
|
|
EBITDA | -202 -202 |
44%
44%
|
EBIT (Operating Income) EBIT | -210 -210 |
35%
35%
|
Net Profit | -217 -217 |
45%
45%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Keith Gottesdiener |
Employees | 234 |
Founded | 2019 |
Website | www.primemedicine.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.